中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2009年
8期
830-832
,共3页
徐鸿绪%王东%陈连周%周娟%钟佛添%曾文涛
徐鴻緒%王東%陳連週%週娟%鐘彿添%曾文濤
서홍서%왕동%진련주%주연%종불첨%증문도
非小细胞肺癌%丙酮酸激酶%肿瘤标志
非小細胞肺癌%丙酮痠激酶%腫瘤標誌
비소세포폐암%병동산격매%종류표지
Non-small cell lung cancer%Pyruvate kinase%Tumor marker
目的 探讨非小细胞肺癌(NSCLC)患者治疗前后血浆中肿瘤型M2丙酮酸激酶(TuM2-PK)的表达水平及其与肿瘤的近期疗效及预后的关系.方法 用ELISA法分别检测83例NSCLC患者(其中31例NSCLC患者手术治疗,52例患者失去外科手术机会而行内科治疗)和106例健康对照者血浆中的TuM2-PK表达水平,并进行24个月的随访.结果 NSCLC手术后血浆TuM2-PK浓度(13.5 U/ml)与术前(25.4U/ml)相比,差异有统计学意义(P<0.05).经内科治疗后,缓解组血浆TuM2-PK浓度(11.5 U/ml)与治疗前(22.6 U/ml)相比显著下降(P<0.05);进展组血浆TuM2-PK浓度(60.8 U/ml)与治疗前(23.7 U/ml)相比显著升高(P<0.05);稳定组血浆TuM2-PK浓度治疗前后差异无统计学意义(P>0.05).手术后TuM2-PK阳性率显著下降,而化疗后阳性率下降不明显.在随访期间,手术后TuM2-PK阳性患者肿瘤复发或转移率(67%,6/9)高于术后阴性患者(5%,1/20).结论 检测NSCLC患者血中肿瘤标志物TuM2-PK表达水平对预测肿瘤微转移有一定的临床意义,有助于疗效的评估以及预后的预测.
目的 探討非小細胞肺癌(NSCLC)患者治療前後血漿中腫瘤型M2丙酮痠激酶(TuM2-PK)的錶達水平及其與腫瘤的近期療效及預後的關繫.方法 用ELISA法分彆檢測83例NSCLC患者(其中31例NSCLC患者手術治療,52例患者失去外科手術機會而行內科治療)和106例健康對照者血漿中的TuM2-PK錶達水平,併進行24箇月的隨訪.結果 NSCLC手術後血漿TuM2-PK濃度(13.5 U/ml)與術前(25.4U/ml)相比,差異有統計學意義(P<0.05).經內科治療後,緩解組血漿TuM2-PK濃度(11.5 U/ml)與治療前(22.6 U/ml)相比顯著下降(P<0.05);進展組血漿TuM2-PK濃度(60.8 U/ml)與治療前(23.7 U/ml)相比顯著升高(P<0.05);穩定組血漿TuM2-PK濃度治療前後差異無統計學意義(P>0.05).手術後TuM2-PK暘性率顯著下降,而化療後暘性率下降不明顯.在隨訪期間,手術後TuM2-PK暘性患者腫瘤複髮或轉移率(67%,6/9)高于術後陰性患者(5%,1/20).結論 檢測NSCLC患者血中腫瘤標誌物TuM2-PK錶達水平對預測腫瘤微轉移有一定的臨床意義,有助于療效的評估以及預後的預測.
목적 탐토비소세포폐암(NSCLC)환자치료전후혈장중종류형M2병동산격매(TuM2-PK)적표체수평급기여종류적근기료효급예후적관계.방법 용ELISA법분별검측83례NSCLC환자(기중31례NSCLC환자수술치료,52례환자실거외과수술궤회이행내과치료)화106례건강대조자혈장중적TuM2-PK표체수평,병진행24개월적수방.결과 NSCLC수술후혈장TuM2-PK농도(13.5 U/ml)여술전(25.4U/ml)상비,차이유통계학의의(P<0.05).경내과치료후,완해조혈장TuM2-PK농도(11.5 U/ml)여치료전(22.6 U/ml)상비현저하강(P<0.05);진전조혈장TuM2-PK농도(60.8 U/ml)여치료전(23.7 U/ml)상비현저승고(P<0.05);은정조혈장TuM2-PK농도치료전후차이무통계학의의(P>0.05).수술후TuM2-PK양성솔현저하강,이화료후양성솔하강불명현.재수방기간,수술후TuM2-PK양성환자종류복발혹전이솔(67%,6/9)고우술후음성환자(5%,1/20).결론 검측NSCLC환자혈중종류표지물TuM2-PK표체수평대예측종류미전이유일정적림상의의,유조우료효적평고이급예후적예측.
Objective To study the expression of tumor type M2 pyruvate kinase(tumor M2-PK) in nonsmall cell lung cancer (NSCLC) and their correlation with treatment response and prognosis.Methods The concentration of tumor M2-PK in plasma was detected by ELISA in 106 healthy controls and 83 NSCLC patients.The patients were followed for 24 months.Results The patients after surgical operation showed marked reduction in plasma tumor M2-PK level(13.5 U/ml vs 25.4 U/ml,P<O.05).In the 15 patients with tumor remission the tumor M2-PK level(11.5 U/ml) was significantly lower than that(22.6 U/ml) before treatment(P<0.05).In the 20 patients with progressive disease the tumor M2-PK level(60.8 U/ml) was significantly higher than that(23.7 U/ml) of pretreatment(P<0.05).The tumor M2-PK concentration did not differ signigicantly before and after treatment in 17 patients with stable disease.The positive rates of tumor M2-PK decreased significantly after operation,but there was no significant change after chemotherapy.In the follow-up,the rate of relapse and metastasis was higher in patients Conclusions Plasma tumor M2-PK might be a useful marker in the detection of tumor mierometastases in NSCLC,and in evaluating treatment response and prognosis.